Canada Markets open in 3 hrs 57 mins

Mesoblast Limited (MEOBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.6416+0.0174 (+2.79%)
At close: 09:45AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.6242
Open0.6416
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6416 - 0.6416
52 Week Range0.4400 - 1.4700
Volume1,200
Avg. Volume1,429
Market Cap415.378M
Beta (5Y Monthly)2.36
PE Ratio (TTM)N/A
EPS (TTM)-0.1560
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Appendix 4C Quarterly Activity Report

    Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022NEW YORK, July 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended June 30, 2022. Financial highlights Net cash usage for operating activities in the quarter was reduced by 33%, or US$6.8 million, to US$13.9 million compared with US$20.7 million in the comparative q

  • GlobeNewswire

    Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management

    NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L, its allogeneic “off-the-shelf” product candidate for the treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF), will be highlighted in a panel discussion titled “Late-Stage Advancements in Heart Failure Therapeutics and Management”, presented by Maxim Group LLC and hosted by

  • Simply Wall St.

    The past five years for Mesoblast (ASX:MSB) investors has not been profitable

    We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...